脳卒中の治療のための代替戦略:将来的なランダム化対照試験
1Department of Medicine, Guy's, King's and St Thomas's School of Medicine, London, UK. lalit.kalra@kcl.ac.uk
Lancet (London, England)
|October 19, 2000
まとめ
専門的な脳卒中ユニットは,脳卒中チームやホームケアと比較して,死亡率と施設入院を大幅に削減します. この組織的なケアにより,患者の治療成果が向上し,脳卒中後の長期的な依存が軽減されます.
科学分野:
- 神経学 神経学とは
- 公衆衛生は公衆衛生である.
- ヘルスケア・マネジメント・ヘルスケア・マネジメント
背景:
- 組織された専門的な脳卒中治療は,患者の治療結果を改善します.
- 異なる脳卒中ケア組織モデルの比較効果は不明である.
- この研究では,脳卒中ユニットと脳卒中チームと家庭内ケアを比較して評価しています.
研究 の 目的:
- 脳卒中ユニットのケアと,脳卒中チームサポートと自宅での脳卒中ケアとの効果を比較する.
- 急性脳卒中患者の管理のための最適な組織モデルを決定する.
- 患者の死亡率,制度化,機能的独立性に対するケア組織の影響を評価する.
主な方法:
- 457人の急性脳卒中患者が参加した単盲,ランダム化制御試験です.
- 患者は,発症から72時間以内に,脳卒中ユニット,脳卒中チームサポートのある一般病棟,または自宅での脳卒中ケアに割り当てられました.
- 死亡または入院を含むアウトカムは,治療意図分析を使用して3,6,および12ヶ月で評価されました.
主要な成果:
- 脳卒中ユニットでの介護は,脳卒中チーム (14%対30%) と自宅での介護 (14%対24%) と比較して,1年後に死亡率または施設入院率が著しく低下しました.
- 脳卒中ユニットで治療を受けた患者の割合は,脳卒中チーム (66%) や家庭内ケア (71%) と比較して,1年後に重度の障害がない状態で生きている割合が高く (85%) でした.
- これらの効果は,脳卒中後3ヶ月と6ヶ月で一貫して観察されました.
結論:
- 脳卒中ユニットは,脳卒中後の死亡率,施設収容,および長期的依存度を低減する上で優れた有効性を示しています.
- 専門の脳卒中治療室は,脳卒中チームサポートや自宅でのケアによる一般病棟よりも良い結果をもたらします.
- この発見は,急性脳卒中管理のための専用脳卒中ユニットの実施を支持する.
関連する概念動画
01:13Randomized Experiments
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
Simple randomization
Simple...
01:16Crossover Experiments
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
01:11Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
01:20Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...